Growth arrest on inhibition of nonsense-mediated decay is mediated by noncoding RNA GAS5. by Mourtada-Maarabouni, M & Williams, GT
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 358015, 9 pages
http://dx.doi.org/10.1155/2013/358015
Research Article
Growth Arrest on Inhibition of Nonsense-Mediated Decay Is
Mediated by Noncoding RNA GAS5
Mirna Mourtada-Maarabouni and Gwyn T. Williams
Institute for Science and Technology in Medicine and School of Life Sciences, Keele University, Huxley Building, Keele ST5 5BG, UK
Correspondence should be addressed to Mirna Mourtada-Maarabouni; m.m.maarabouni@keele.ac.uk
and Gwyn T. Williams; g.t.williams@keele.ac.uk
Received 5 April 2013; Accepted 19 September 2013
Academic Editor: Xudong Huang
Copyright © 2013 M. Mourtada-Maarabouni and G. T. Williams. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Nonsense-mediated decay is a key RNA surveillance mechanism responsible for the rapid degradation of mRNAs containing
premature termination codons and hence prevents the synthesis of truncated proteins. More recently, it has been shown
that nonsense-mediated decay also has broader significance in controlling the expression of a significant proportion of the
transcriptome. The importance of this mechanism to the mammalian cell is demonstrated by the observation that its inhibition
causes growth arrest. The noncoding RNA growth arrest specific transcript 5 (GAS5) has recently been shown to play a key role in
growth arrest induced by several mechanisms, including serum withdrawal and treatment with the mTOR inhibitor rapamycin.
Here we show that inhibition of nonsense-mediated decay in several human lymphocyte cell lines causes growth arrest, and
siRNA-mediated downregulation of GAS5 in these cells significantly alleviates the inhibitory effects observed. These observations
hold true for inhibition of nonsense-mediated decay both through RNA interference and through pharmacological inhibition by
aminoglycoside antibiotics gentamycin and G418. These studies have important implications for ototoxicity and nephrotoxicity
caused by gentamycin and for the proposed use of NMD inhibition in treating genetic disease. This report further demonstrates
the critical role played by GAS5 in the growth arrest of mammalian cells.
1. Introduction
GAS5 (growth arrest-specific transcript 5) was identified
using a functional screen through its ability to suppress
apoptosis in a mouse thymoma cell line [1]. This gene is
encoded at 1q25, a chromosomal locus which has been
associated both with leukaemia and lymphoma [2–4] and
with systemic lupus erythematosus (SLE) [5–8].
GAS5 was initially isolated from a subtraction cDNA
library as part of a strategy intended to identify genes
enriched on growth arrest [9]. GAS5 encodes small nucleolar
RNAs (snoRNAs) in its introns, and its exons contain a
small open reading frame (ORF) which does not encode a
functional protein [10]. The snoRNAs expressed from the
intronic regions of GAS5 are involved in the biosynthesis
and processing of ribosomal RNA, which has always been
assumed to be an essentially housekeeping role. However, a
number of lines of evidence have emerged recently which
indicate the involvement of snoRNAs in regulating cell
growth and proliferation [11]. Gene expression studies have
shown a significant upregulation of GAS5 by oncogenic
kinases associated with myeloproliferative disorders [12].
GAS5 is also involved in a chromosomal rearrangement with
Notch 1 in radiation-induced thymic lymphoma [13]. Most
importantly, GAS5 has been shown to play critical roles
in normal growth arrest in both primary and transformed
human cells [14, 15] and in the inhibition of human T-
cell proliferation produced by mTOR antagonists such as
rapamycin and its analogues [16].
GAS5 is transcribed as a 5󸀠-terminal oligopyrimidine
(5󸀠TOP) RNA and thus belongs to a class of transcripts
characterised by an oligopyrimidine tract sequence at its
5󸀠 end. Other 5󸀠TOP RNAs encode ribosomal proteins,
as well as other proteins involved in protein synthesis
(reviewed by Meyuhas and Dreazen [17]). 5󸀠TOP transcripts
share some distinctive characteristics in common, includ-
ing the inhibition of their translation by the immuno-
suppressant rapamycin [18]. An additional characteristic of
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5󸀠TOP mRNAs is that they are subject to growth-dependent
translational control, which explains the previously reported
posttranscriptional accumulation of GAS5mRNA in growth-
arrested cells [19]. The complex processing of GAS5 tran-
scripts results in the production of many different splice
variants which are normally associated with ribosomes [19].
The open reading frame of human spliced GAS5 is small, and
its termination codon is found in an early exon, suggesting
that these transcripts are subject to nonsense-mediated decay
(NMD) when translated [19, 20]. In growing cells, the active
translation of all 5󸀠TOP RNAs leads to rapid degradation of
the GAS5 transcripts by NMD, whereas, in growth arrested
cells, inhibition of translationwould be expected to lead to the
accumulation of GAS5 transcripts, since NMD only affects
mRNAs which are being translated [19].
The NMD pathway is an essential process in cell growth
and development. It acts as an RNA surveillance mechanism
by promoting degradation of mRNAs containing premature
stop codons [21] and also regulates the expression of a
small but significant fraction of the cell’s transcriptome [22].
Absence of NMD results in the accumulation of transcripts
containing premature stop codons leading to the translation
and stabilisation of truncated proteins, which have deleteri-
ous effects for the cell (reviewed by Brogna and Wen [23],
and by Nicholson andMu¨hlemann [24]).TheDNA and RNA
helicase UPF1 (up-frameshift suppressor 1) plays a key role in
NMD [25, 26], and consequently the depletion of UPF1 by
RNAi inhibits NMD [27]. UPF1 has also been found to be
essential for human cells to complete DNA replication and
for genomic stability [28]. Since GAS5 is also important for
the control of the survival and proliferation of lymphocytes
[14] and its abundance within the cell is controlled by NMD,
we set out to test the working hypothesis that the effects of
UPF1 could be mediated in part through the regulation of
GAS5 mRNA levels, using RNA interference to inhibit NMD
by downregulating UPF1.
The aminoglycoside antibiotics G418 and gentamycin
bind to ribosomes and interfere with chain elongation, so
that, at high concentrations, they block protein synthesis,
and, at lower concentrations, they inhibit NMDwhile protein
synthesis continues [29, 30]. We therefore used these com-
pounds at low concentrations as an independent strategy for
inhibiting NMD.
2. Materials and Methods
2.1. Cell Culture. The B-lymphoblastoid cell line BJAB and
the cloned human T-leukemic cell lines CEM-C7 (clone
CKM1) and Jurkat (clone JKM1) were maintained in RPMI-
1640 medium (Sigma) supplemented with 10% heat inacti-
vated fetal calf serum (HyClone), 2mM L-glutamine, at 37∘C
in a 5% CO
2
humidified incubator.
2.2. Determination of Cell Viability. Cell viability was deter-
mined by the Live/Dead viability assay (Molecular probes;
cat. no. 03224). 200𝜇L of cells (2 × 105 cells/mL) was
incubated in 96 well plates for 48 hours. An aliquot of
the control or treated cells was added to 100mL of the
combined Live/Dead assay reagents (as instructed by the
manufacturer). Cells were then incubated for 40 minutes
at room temperature. Live cells stained with the green
fluorescent dye and dead cells stainedwith the red fluorescent
dye were visualised and counted using a Nikon Eclipse E400
fluorescence microscope.
2.3. DNA Assay (5-Bromo 2󸀠-Deoxyuridine (BrdU) Incorpora-
tion). The effects of UPF1 and GAS5 down-regulation on the
proliferation of CEM-C7, Jurkat, and BJAB cells were assessed
by bromodeoxyuridine (BrdU) incorporation during DNA
synthesis using a colorimetric ELISAKit (Roche Diagnostics,
Germany; cat. no. 11647229001), following themanufacturer’s
instructions. In brief, 200𝜇L cells (2 × 105 cells/mL) was
cultured in flat-bottom 96-well plates for 48 h. Subsequent
to labelling with 10 𝜇M of BrdU (for the final 18 h of the
incubation period), DNA was denatured and cells were
incubated with anti-BrdU monoclonal antibody, prior to the
addition of substrate. The absorbance of the samples was
measured using a microplate reader (Wallac 1420 Victor
Plate Reader) at 450 nm with the absorbance at 690 nm as
reference.
2.4. Clonogenic Assay. Long-term survival of transfected cells
treated with G418 (Invitrogen) or gentamycin (Sigma) was
assessed by the ability of the cells to form colonies in soft
agar. An equal proportion of culture from each experimental
condition was diluted in 5mL Iscove’s medium (Sigma)
containing 20% heat inactivated fetal calf serum, 10% cell-
conditionedmedium, and 0.3% noble agar (Difco) and plated
in 60mm dishes, overlaid with 2.5mL Iscove’s complete
medium containing 10% cell conditioned medium. Colonies
were counted following 2-3 weeks incubation at 37∘C in 5%
CO
2
and 95% air.
2.5. RNA Interference. Transfection of UPF1, GAS5, and
control siRNAs was as previously described [14]. Three
different GAS5 siRNAs (small interfering RNAs) were
designed by Ambion (siRNAs id 290458 (GAS5siRNA2);
290460 (GAS5siRNA1), 290459 (GAS5siRNA3); reference
sequence AF141346). Three different UPF1 siRNAs (siRNAs
id 12379 (UPF1 siRNA1); 142478 (UPF1 siRNA2); 12197
(siRNA3)) were also designed by Ambion. Negative control
siRNA ((−)siRNA cat. no. 4605) was also purchased from
Ambion. All siRNAs were purchased, already HPLC purified,
annealed, and ready to use. To analyse the siRNA transfection
efficiency, siRNA duplexes were labelled with Cy3 using the
Silencer siRNA labelling kit (Ambion; cat. no. 1632), following
the manufacturer’s instructions, and transfection efficiencies
(fluorescently labelled cells after 48 h) were 70%–80%.On the
day before transfection, cells were split and cultured in RPMI
supplemented with 10% FCS. On the day of transfection,
106 cells (CEM-C7, Jurkat or BJAB) were centrifuged and
washed once in Opti-MEM 1 (Invitrogen; no. 51985-026)
before resuspension in 400 𝜇L Optimem. Cells were then
incubatedwith 20 nMor 100 nMsiRNAduplex for 10minutes
at room temperature in a 0.4 cm electroporation gap cuvette.
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Cells were electroporated for 25milliseconds at 248V (CEM-
C7) or 293V (Jurkat and BJAB) 1050 𝜇F using a Biorad
Gene Pulser. Following electroporation, cells were incubated
at room temperature for 20min prior to transfer to 6 well
plates containing Iscove’s medium (Sigma) supplemented
with 2mM glutamine and 20% heat-inactivated FCS. The
analysis of specific silencing of GAS5 expression was carried
out after 48 hours, using real-time RT-PCR.
2.6. Real Time RT-PCR. Real-time RT-PCR was performed
using 2𝜇L of the cDNA prepared as described for RT-PCR
above (equivalent to 500 ng of the total RNA) and TaqMan
MGB probes and primers specific to human UPF1 (Applied
Biosystems; assay id Hs00161289 m1) and human GAS5
(Exon 12: designed by Applied Biosystems; Forward primer
CTTCTGGGCTCAAGTGATCCT; Reverse primer TTGT-
GCCATGAGACTCCATCAG; reporter CCTCCCAGTGGT-
CTTT) with eukaryotic 18S rRNA as an endogenous control
(Applied Biosystems; assay id Hs99999901 s1), according to
the manufacturer’s instructions. Quantitation of GAS5 and
UPF1 in cells transfected with GAS5 and UPF1 siRNAs con-
structs relative to (−)siRNA-transfected cells was determined
using the comparative CT method, using untransfected cells
as calibrators.TheABI Prism 7000 sequence detection system
was used tomeasure real-time fluorescence, and data analysis
was performed using ABI Prism 7000 SDS software.
2.7. Statistical Analysis. Data are presented as the mean ±
standard error of the mean (s.e.m.). Statistical significance
was determined by analysis of variance using Origin 6.1. A P
value of <0.01 was considered statistically significant.
3. Results
3.1. Downregulation of UPF1 Reduces Cell Viability and
Inhibits Cell Proliferation. Initial experiments were carried
out to study the physiological importance of UPF1 in the
human B-cell line BJAB and the T-cell lines Jurkat and CEM-
C7, which all proliferate continuously in culture without
stimulation. We therefore used RNA interference (RNAi)
to investigate the effects of downregulation of endogenous
UPF1 expression in these cells. Transfecting the cells with
UPF1 siRNA1 caused downregulation of UPF1 by 60%–65%,
as shown in Figure 1(a) (the other 2 siRNAs tested were
not effective). Downregulation of UPF1 caused a substantial
reduction in viability of cell populations in the three cell lines
at 48 h and 72 h (Figures 1(b) and 1(c)). Cell proliferation of
BJAB, CEM-C7, and Jurkat cells was also inhibited as a result
of UPF1 down-regulation (Figure 1(d)).
3.2. The Inhibitory Effect of UPF1 on Cell Viability and Growth
Is Mediated through an Increase in Endogenous GAS5 mRNA
Levels. Previous work has shown that depletion of UPF1 in
Hela cells was accompanied by an increase in the levels of
GAS5 transcripts [31]. We therefore investigated the level
of GAS5 in UPF1siRNA-transfected lymphoid cells. Down-
regulation of UPF1 in the three cell lines, BJAB (Figure 2(a)),
Jurkat (Figure 2(b)), and CEM-C7 (Figure 2(c)), led to sig-
nificant accumulation of endogenous GAS5 mRNA 48 h and
72 h after transfection, as confirmed by qRT-PCR (Figure 2).
Previous results have shown that overexpression of GAS5
causes both an increase in cell death and a reduction in
the rate of progression through the cell cycle both in T-
cell lines and in untransformed human peripheral blood
T-cells [14], producing effects which are somewhat similar
to the effects observed with UPF1 downregulation (Figures
1(b), 1(c), and 1(d); Azzalin and Lingner, 2006 [28]). Since
UPF1 down-regulation results in the accumulation of GAS5
mRNA (Figure 2), our working hypothesis was that the
inhibitory effects of UPF1 on cell viability and growth
could be mediated, to some extent, through the increase
in endogenous GAS5 mRNA levels. Using GAS5-specific
siRNAs [14], we studied the effects of GAS5 downregulation
on the viability of the cells transfected with UPF1 siRNA.
CEM-C7, Jurkat, and BJAB cells were transfected with UPF1-
specific siRNA and negative control siRNA ((−)siRNA). 24 h
after transfection, control cells (transfected with negative
control siRNA) and cells transfected with UPF1 siRNA
were transfected with (−)siRNA or GAS5-specific siRNAs
(downregulation of 60%–65% for siRNA targeting UPF1 and
65%–73% for all three siRNAs targetingGAS5was confirmed
by quantitative RT-PCR; data not shown). As similar results
were obtained from all three GAS5 siRNAs, data obtained
using only one GAS5 siRNA are shown. As shown previously
[14], knockdown of GAS5 in BJAB, Jurkat, and CEM-C7 cells
caused some increase both in viable cell number (Figure 3(a))
and in cell proliferation (Figure 3(b)). Down-regulation of
UPF1 caused a decrease in the number of viable cells in BJAB,
Jurkat, and CEM-C7 cells (Figure 3(a)) and a clear reduction
in cell proliferation in all cell types (Figure 3(b)), confirming
the results obtained earlier. However, GAS5-specific siRNA
significantly alleviated the effects of UPF1 down-regulation
in all three cell lines (Figures 3(a) and 3(b)), indicating that
the increase in cell death and inhibition of cell proliferation
mediated by UPF1 down-regulation is mediated, at least in
part, by the accumulation of GAS5 mRNA levels. Since the
transfection efficiency was 70% to 80%, the true protective
effect of GAS5 down-regulation is likely to be even greater
than demonstrated here.
3.3. Downregulation of Endogenous GAS5 Reverses the
Inhibitory Effects of Aminoglycoside Antibiotics Gentamycin
and G418. It is well established that aminoglycoside antibi-
otics such as gentamycin and G418 can induce translational
read-through of nonsense codons and thus suppress NMD
[29, 30]. We therefore investigated whether down-regulation
of GAS5 has any effect on the growth inhibitory effects
of gentamycin and G418. CEM-C7, Jurkat, and BJAB cells
were transfected with GAS5 siRNA2 and negative control
siRNA. 48 h after transfection, control cells (transfected with
negative control siRNA ((−)siRNA) and cells transfected with
GAS5 siRNA2 (down-regulation of 65%–73%, as confirmed
by quantitative RT-PCR; data not shown) were treated with
G418 or gentamycin. As Figure 4(a) shows, GAS5-siRNA
significantly protected colony-forming ability after treatment
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Figure 1: UPF1-specific siRNA increases cell death and inhibits cell proliferation in the human T-cell lines Jurkat and CEM-C7 and in the
B-lymphoblastoid cell line BJAB. (a) Cells were transfected with 3 different specific UPF1 siRNAs or negative control siRNA ((−)siRNA) and
cultured at 37∘C. After 72 h the expression of endogenous UPF1 in the siRNA transfected cells was determined by real-time RT-PCR (mean ±
s.e.m. from three separate experiments) and expressed relative to untransfected controls. ((b)–(d))Cellswere transfectedwithUPF1-siRNA1 or
negative control siRNA ((−)siRNA) and cultured at 37∘C. Viable cell numbers were determined after 48 h (b) and 72 h (c) by the LIVE/DEAD
assay (Section 2.2). Results are represented as mean ± s.e.m. from three independent experiments. (d) Cell proliferation was measured after
48 h using the BrdU colorimetric ELISA assay. Results are represented as mean ± s.e.m. from three independent experiments. ∗𝑃 < 0.01
compared with (−)siRNA.
with gentamycin (1.7- to 2-fold) in Jurkat (1.7-fold), CEM-
C7 (1.6-fold), and BJAB (1.9-fold) cells. Downregulation of
GAS5 significantly alleviated the inhibitory effects of G418
(0.5 𝜇g/mL) on colony forming ability in CEM-C7 (2-fold)
and Jurkat cells (1.9-fold) but the alleviation is not statistically
significant at this concentration of G418 for BJAB cells
(Figure 4(b)). Further experiments with lower concentrations
showed that transfecting BJAB cells with GAS5 siRNA2 did
significantly protect against the loss of colony forming ability
induced by lower concentrations of G418 (0.3 and 0.4𝜇g/mL;
Figure 4(c); P, 0.01).
4. Discussion
NMD is one of the best characterized RNA surveillance
mechanisms; it protects the cell from the potentially detri-
mental effects of truncated proteins by detecting mRNA
transcripts containing premature termination codons in their
ORF and committing them to rapid decay (reviewed by
Brogna and Wen [23] and Nicholson and Mu¨hlemann [24]).
The well-conserved DNA and RNA helicase UPF1 is a crucial
component of the core NMD machinery, and expression of
a dominant-negative human UPF1 mutant, which contains
BioMed Research International 5
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Figure 2: Down-regulation of UPF1 increases GAS5 mRNA levels. The human T-cell lines Jurkat and CEM-C7 and in the B-lymphoblastoid
cell line BJABwere transfectedwith specificUPF1siRNA1 or negative control siRNA ((−)siRNA) and cultured at 37∘C. 48 h, 72 h, and 96 h after
transfection, and the expression of endogenous GAS5mRNA in the siRNA transfected BJAB (a), Jurkat (b), and CEM-C7 (c) was determined
by real-time RT-PCR using the comparative CT method, normalised with 18S RNA as an internal control. The results are represented as the
mean ± s.e.m. from three separate experiments. ∗𝑃 < 0.01 compared with (–)siRNA.
a point mutation (R844C) in its RNA helicase domain, has
been shown to impair NMD activation [32]. In addition, loss
of UPF1 in a number of human cell lines has been reported
to lead to impairment of NMD and to inhibition of cell
proliferation [28]. In the present study, down-regulation of
UPF1 caused a marked decrease in viability and proliferation
of cell populations in the three cell lines examined (Figure 1).
All these observations strongly suggest that UPF1 plays an
important role in regulating the survival and proliferation of
human lymphoid cell lines.These data are consistent with the
observations that genetic disruption of the murine ortholog
of UPF1 (RENT1) is embryonically lethal [33] (Medghalchi et
al., 2001) and that mutation in UPF1 is lethal in Drosophila
[26].
In Hela cells, depletion of hUPF1 caused an increase in
the levels of GAS5 transcripts [31]. In addition, knockdown of
SMG1, 8 and 9 (forming part of the SMG1 complex, the phos-
phatidylinositol 3-kinase that regulates the phosphorylation
state and function of UPF1), also resulted in an accumulation
of GAS5 mRNA [34]. The present work also shows that
down-regulation of UPF1 caused a significant accumulation
of endogenous GAS5 mRNA in all the cell lines studied
(Figure 2). Our results also indicate that, in both T-cell lines
and B-cell lines, the inhibitory effects of UPF1 on cell viability
and growth are, at least in part,mediated through the increase
in endogenous GAS5 mRNA levels, since down-regulation
of GAS5 significantly alleviated the effects of UPF1 down-
regulation (Figure 3).
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Figure 3: Down-regulation of GAS5 alleviates the inhibitory effects of UPF1 siRNA on cell viability and proliferation. CEM-C7, Jurkat, and
BJAB cells were transfected with either control (−)siRNA or UPF1-siRNA1. 24 h after transfection, control cells and cells transfected with
UPF1 siRNA were transfected with (−)siRNA or GAS5 siRNAs. Viable cell number (a) and cell proliferation (b) were determined after 72 h.
Results are calculated as percentage viable cell number and absorbance relative to controls transfected with (−)siRNA. Data represent means
± s.e.m. from three independent experiments. ∗𝑃 < 0.01 compared to UPF1 siRNA, (−)siRNA1-transfected cells.
Of all the factors which play essential roles in NMD
[35], UPF1 is functionally the most important and has also
been reported to have additional functions independent of
NMD. UPF1 is involved in the degradation of replication-
dependent histone mRNA upon replication inhibition and
at the end of S phase [36] and is essential for S phase pro-
gression [28].Thepresent study demonstrates the importance
of UPF1 in regulating the growth and survival of human
lymphocytes and provides evidence that a substantial part of
the antiproliferative effects of inhibition of NMD is mediated
through GAS5. Given the established importance of GAS5
in the control of lymphoid cell proliferation and survival
and the accumulation of GAS5 mRNA on UPF1 down-
regulation, the alleviation of the effects of UPF1 knockdown
by downregulating GAS5 indicates that the modulation of
GAS5 transcript levels connects NMD to the control of cell
division and survival. On the other hand, the incomplete
rescue by GAS5 siRNAs (Figure 3) indicates that additional
genes must also be involved.
At concentrations below those which block protein
synthesis, aminoglycoside antibiotics gentamicin and G418
inhibit NMD by allowing read-through of stop codons [29,
30].This independent strategy of pharmacological inhibition
of NMD also results in a reduction in colony-forming ability,
and these effects were also substantially alleviated by down-
regulation of GAS5 (Figure 4). This provides important
independent evidence supporting the proposed role of GAS5
in the cytotoxic and cytostatic effects of NMD inhibition.
As GAS5 is only one of many genes which are affected by
inhibition of NMD, such inhibition is likely to be the most
important effect of these aminoglycoside antibiotics at the
lowest lethal levels.
The effects of aminoglycoside antibiotics on NMD have
two important clinical implications. Firstly, ototoxicity and
nephrotoxicity are important side effects of clinical treatment
with gentamicin [37, 38]. The present report suggests that, at
the relatively low concentrations likely to be encountered in
vivo, the cytotoxic effects observed on treatment with these
antibiotics may be mediated by inhibition of NMD and the
consequent increase in GAS5 levels. Secondly, inhibition of
NMD has been proposed as a clinical treatment for genetic
abnormalities, such as a proportion of cystic fibrosis cases,
that are caused by nonsense mutations producing premature
termination codons within the coding sequence (reviewed
by Bhuvanagiri et al. [39]). The present report suggests that
pharmacological inhibition of NMD as a clinical treatment
will need to employ specific targeting strategies [39] rather
than blanket inhibition of NMD in order to avoid the
cytostatic and cytotoxic consequences of stimulation of GAS5
levels.
GAS5 RNA levels appear to be regulated primarily
through changes in its rate of degradation rather than
through changes in its rate of transcription [19, 40]. As for
other 5’ TOPRNAs,GAS5mRNA stability is dependent on its
translation, which is controlled, at least in part, by the mTOR
pathway [18, 19], and on its degradation by theNMDpathway,
as shown both previously [19, 20] and in the present study
(Figure 2). Inhibition of mTOR and inhibition of NMD both
inhibit cell proliferation, and in both cases, a substantial part
of the inhibitory effect ismediated throughGAS5 (Mourtada-
Maarabouni et al. [16] and Figure 3), indicating that GAS5
frequently plays a critical role in growth arrest inmammalian
cells.
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Figure 4: Down-regulation of GAS5 alleviates the inhibitory effects of aminoglycoside antibiotics on the colony forming ability of the human
T-cell lines Jurkat and CEM-C7 and the B-lymphoblastoid cell line BJAB. CEM-C7, Jurkat, and BJAB cells were transfected with either control
(−)siRNA or GAS5 siRNA2. 48 h after transfection, transfected cells were treated with gentamycin (100𝜇g/mL) (a), G418 (0.5𝜇g/mL) (b), or
G418 (0.3–0.5 𝜇g/mL) on BJAB cells (c) for 72 h. Colony forming ability was then determined by plating in soft agar. Results are calculated as
percentage colony numbers relative to controls incubated in the absence of aminoglycoside antibiotics. Means ± s.e.m. from four independent
experiments are shown. ∗𝑃 < 0.01 compared to (−)siRNA.
Previous studies have highlighted the significance of
changes in the level of GAS5 expression for the control of
cell division and survival and demonstrated a crucial role
for this noncoding RNA in the control of growth arrest,
apoptosis, and the cell cycle [14–16]. In addition, GAS5
transcript levels were found to be significantly reduced in
breast cancer samples relative to adjacent unaffected normal
breast epithelial [15] and low tumour GAS5 expression has
recently been associated with poor prognosis in patients with
breast cancer and head and neck squamous cell carcinoma
[41]. The remarkable effects of changes of GAS5 expression
on the control of cell apoptosis and growth reported here and
in other studies [14, 16] indicate the potential significance of
this gene in the development and progression of cancer [11]
8 BioMed Research International
and highlight the importance of further investigation into
the role of GAS5 dysregulation in autoimmune disease and
oncogenesis.
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